BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in a transaction valued at up to $285 million, combining upfront cash with contingent milestone payments. The acquisition brings Mersana’s leading antibody-drug conjugate (ADC) candidate, Emiltatug Ledadotin (Emi-Le)—a B7-H4-targeting therapeutic—into Day One’s oncology development pipeline. The merger underscores Day One’s mission to deliver novel, targeted cancer therapies across age groups, strengthening its scientific footprint in precision oncology.
Science Significance
Scientifically, the acquisition centers on Emi-Le, an ADC developed using Mersana’s Dolasynthen platform, designed for enhanced stability, targeted payload delivery, and reduced toxicity. The molecule targets B7-H4, a tumor-associated antigen highly expressed in adenoid cystic carcinoma (ACC) and triple-negative breast cancer (TNBC). Early clinical data demonstrated promising tumor responses in ACC patients, an area with no established standard of care. By absorbing Mersana’s ADC expertise, Day One advances its portfolio into the next generation of targeted therapies that combine antigen specificity, optimized linker chemistry, and precise drug-to-antibody ratios, aligning with modern ADC engineering standards.
Regulatory Significance
From a regulatory perspective, the Emi-Le program is positioned to pursue orphan designation, fast track, and potentially breakthrough therapy pathways due to the rarity and high unmet need of ACC. The acquisition includes a structured milestone schedule tied to registration-enabling trials, regulatory submissions, and commercial launch objectives, reflecting the complex approval environment for emerging ADCs. With increasing regulatory scrutiny on safety profiles, manufacturing consistency, and biomarker-driven patient selection, Day One will integrate Mersana’s regulatory groundwork to streamline IND/CTA amendments and future BLA submissions.
Business Significance
Advertisement
The transaction enhances Day One’s strategic position in oncology and expands its late-stage development portfolio. With ADCs projected to exceed $20 billion globally, this acquisition provides commercial and scientific leverage in a high-growth therapeutic area. The deal provides an opportunity for Day One to diversify revenue potential, accelerate clinical timelines, and consolidate its leadership in molecularly targeted pediatric and adult oncology. The CVR structure aligns payment milestones with value creation, minimizing acquisition risk while advancing high-impact innovation.
Patients’ Significance
For patients—especially those with rare, aggressive cancers—the acquisition signals meaningful progress toward new treatment options. ACC patients currently face limited therapy choices, and Emi-Le’s early activity offers hope for improved survival and quality of life. Targeted ADCs minimize systemic toxicity while maximizing tumor-cell killing, delivering a therapeutic approach well aligned with patient-centred oncology. Day One’s focus on therapies “from day one of diagnosis” extends access to both pediatric and adult populations historically underserved in oncology R&D.
Policy Significance
The acquisition supports broader health-policy priorities emphasizing rare-disease innovation, accelerated oncology approvals, and investment in precision-medicine platforms. Governments continue to champion policies that support novel oncology modalities, including incentives for ADC development and orphan oncology trials. Day One’s expansion of a cancer-focused pipeline parallels national and international health-system goals to increase treatment accessibility and improve outcomes for underserved tumor types.
Day One Biopharmaceuticals’ acquisition of Mersana Therapeutics marks a pivotal moment in the advancement of ADC-based oncology treatments. By uniting complementary scientific strengths and clinical ambitions, the companies are poised to accelerate the development of highly targeted therapies for rare and hard-to-treat cancers. This acquisition strengthens Day One’s commitment to addressing unmet patient needs with innovative, precise, and impactful cancer medicines.
Source: Day One Biopharmaceuticals press release
